

# Johnson & Johnson to Provide Latest Updates on Hepatitis C Treatment

*Pierre Raboisson, Head of Medicinal Chemistry at Janssen, to make a keynote address at 16th annual Superbugs and Superdrugs summit*

LONDON , UNITED KINGDOM, February 11, 2014  
/EINPresswire.com/ -- SMi are pleased to announce that Pierre Raboisson, Head of Medicinal Chemistry at Janssen (Johnson & Johnson), will be making a keynote address at the industry established conference on [Superbugs & Superdrugs](http://www.superbugssuperdrugs.com) taking place soon on 5th and 6th March in London, UK.

In recent months, The FDA approved a new drug from Johnson & Johnson (Olysio) for use in treating chronic hepatitis C infections. Currently more than 170 million people are estimated to be infected with the virus. Following on from this, Janssen's Head of Medicinal Chemistry will be presenting attendees with a keynote address entitled: The Latest Treatment for Hepatitis C, Challenges and Opportunities. Highlights will include:

“

Very good and engaging speakers”

*Merck*

- Diseases leading from chronic HCV
- Protease Inhibitor (boceprevir, telaprevir and simeprevir) based triple therapy with pegylated interferon and ribavirin
- New direct-acting antivirals
- Updates on interferon-free combination treatment regimens

regimens

Visit <http://www.superbugssuperdrugs.com> to view presentation details and the full speaker line-up for 2014

The 16th annual conference on Superbugs & Superdrugs is the focal point for everyone working in the market for infectious diseases. Attending provides a unique forum to engage with leading industry experts active in the field. With less than a month until the event takes place, those interested in attending can book online at [www.superbugssuperdrugs.com](http://www.superbugssuperdrugs.com)



Superbugs & Superdrugs will aim to provide attendees tools in:

- Best Practices – Share ideas with industry leaders to identify cutting-edge developments including antibody based strategies as a new method to tackle antimicrobial resistance , pre-clinical developments and new treatments for infection and preventing infection
- Strategy – Aid your antibiotic drug research and hear case study driven presentations from leading pharmaceutical and regulatory KOLS including EFPIA, GSK, BARDA, the European Commission, Johnson & Johnson, Sanofi, MedImmune and Astellas
- Funding - Discover the latest Public/Private Partnerships to combat antimicrobial resistance both in the US and in Europe
- Industry - Learn about hot topics which include antimicrobial stewardship, nanoparticulate oligonucleotide antibacterials and alternative models for tackling antimicrobial resistance
- Join the Debate – Participate in a round table discussion led by the European Commission, EFPIA, BARDA, GSK and TranScrip partners on Antibiotic R&D funding.
- The Future - Look ahead into the European Antibiotic Recovery Plan and analyse global solutions.
- Peer to peer networking - Ample opportunity for discussion, including 2 morning coffee breaks, 2 networking lunches and 2 afternoon tea sessions. Make new contacts, meet old friends and immerse yourself in a universe of new insights.

Previous instalments in the Superbugs & Superdrugs series received positive feedback from the industry including:

"Very well organised conference." – GSK

"Good level of quality." – Janssen

"Very good and engaging speakers." – Merck

"Good topics, mix of research, clinical development and perspectives" - J&J

For further information visit [www.superbugsuperdrugs.com](http://www.superbugsuperdrugs.com)

Superbugs and Superdrugs: A focus on antibacterials

5th & 6th March 2014

Holiday Inn Regents Park, London UK

[www.superbugsuperdrugs.com](http://www.superbugsuperdrugs.com)

Teri Arri

SMi Group Ltd

+44 (0)20 7827 6162

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/190014835>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2023 Newsmatics Inc. All Right Reserved.